Volume Spike Investor

Cerus Corporation (NASDAQ: CERS) is seeing a surge after announcing that the Swiss regulatory body called Swissmedic has approved the use of platelet components treated with Cerus’ INTERCEPT Blood System. The company noted that this approval extends permitted storage time for platelets to seven days with INTERCEPT treatment, compared to five days without treatment.  Be advised that the Swiss market is a small market, but is also a key to other market.  Cerus shares at 8:48 AM EST have already traded 150,000 shares and the last trade was up over 30% at $2.35.  Average volume is about 370,000 shares and the market cap was only $58 million as of the close yesterday.  The 52-week high here is $5,02, so this one is not off its charts. -JON OGG